Journal
TARGETED ONCOLOGY
Volume 4, Issue 4, Pages 253-254Publisher
SPRINGER
DOI: 10.1007/s11523-009-0130-0
Keywords
Sunitinib; Pancreatic carcinoma, VEGF; VEGFR, targeted therapy; Angiogenesis
Categories
Ask authors/readers for more resources
Sunitinib demonstrating efficacy in pancreatic islet cell carcinomas will pave the way for further trials in other neuroendocrine tumor types such as carcinoid, poorly differentiated neuroendocrine disease, and several other endocrine tumors that are dependent on VEGF/VEGFR for angiogenesis. In addition, other drugs with distinct mechanisms of action, such as mTOR inhibitors, currently investigated in phase III trials, may also supply novel options in those diseases to control tumor growth and metastasis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
